CeaseCancer

Pancreatic cancer drug treatment, combined with chemotherapy

Contact us

INNOVATION AT SHEBA MEDICAL CENTER

The Problem

PANCREATIC CANCER DIAGNOSIS IS A CRUEL AND INEVITABLE FATE

- 87% of pancreatic cancer cases are fatal with a median survival time of 11 months
- Usually diagnosed at a late stage, when metastases already spread
- Main treatment is chemotherapy
- Very often cancer returns, resistant to chemotherapy
- All new therapies are largely inefficient, raising survival time by a negligible amount

It's time to give pancreatic cancer patients hope.

The Solution

CeaseCancer treatment

- CeaseCancer treatment is based on recombinant human Klotho protein
- It has a unique Mechanism of Action affecting only cancer cells
- It’s efficacy and safety demonstrated in vivo and in vitro
- Synergy with chemotherapy was demonstrated
- CeaseCancer treatment was developed by Prof. Ido Wolf, head of Oncology Division of TLV Medical Center



Recombinant human Klotho and human KL-1 inhibit tumor growth in xenograft mice model (treatments vs control)

The Market

Pancreatic Cancer Market Size

- Global pancreatic cancer market is expected to reach 7.7$bn dollars by 2030 with a CAGR of 14.1%
- There is an urgent need for new therapies
- CeaseCancer's Edge:
  - Targeted therapy with minimal adverse effects
  - Synergy with current treatments
  - Potential expansion to other cancer types
  - Potential for FDA Fast Track designation



About Us

- CeaseCancer is a portfolio project under BioXL

- BioXL's founders have had management positions in established pharma and startup companies, e.g. Merck-Serono
- BioXL's founders were engaged in establishment of new companies, from the idea to advanced stages, e.g. Ambrosia Bio, Proterec, Biopharm Labs, Enzymogen, PPS, PPSV

- CeaseCancer is intended to be registered as a spin-off, independent company

Finance

- The target of the current fundraising round is 2,000,000 USD
- The funds will enable reaching an inflection point:
  - Completion of PDx animal model and safety
  - Pre-IND meeting with health authorities (e.g FDA)
- At that point, the engagement of pharma companies is anticipated as well as better access to large funding opportunities, that will enable reaching clinical development